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Abstract
The receptor tyrosine kinase MET is a major component controlling the invasive growth program in embryonic
development and in invasive malignancies. The discovery of therapeutic antibodies against MET has been difficult,
and antibodies that compete with hepatocyte growth factor (HGF) act as agonists. By applying phage technology
and cell-based panning strategies, we discovered two fully human antibodies against MET (R13 and R28), which
synergistically inhibit HGF binding to MET and elicit antibody-dependent cellular cytotoxicity. Cell-based phosphor-
ylation assays demonstrate that R13 and R28 abrogate HGF-induced activation of MET, AKT1, ERK1/2, and HGF-
induced migration and proliferation. FACS experiments suggest that the inhibitory effect is mediated by “locking”
MET receptor in a state with R13, which then increases avidity of R28 for the extracellular domain of MET, thus
blocking HGF binding without activating the receptor. In vivo studies demonstrate that the combination of R13/28
significantly inhibited tumor growth in various colon tumor xenograft models. Inhibition of tumor growth was
associated with induction of hypoxia. Global gene expression analysis shows that inhibition of HGF/MET pathway sig-
nificantly upregulated the tumor suppressors KLF6, CEACAM1, and BMP2, the negative regulator of phosphatidyl-
inositol-3-OH-kinase PIK3IP1, and significantly suppressed SCF and SERPINE2, both enhancers of proliferation and
invasiveness. Moreover, in an experimental metastasis model, R13/28 increased survival by preventing the recur-
rence of otherwise lethal lung metastases. Taken together, these results underscore the utility of a dual-antibody ap-
proach for targeting MET and possibly other receptor tyrosine kinases. Our approach could be expanded to drug
discovery efforts against other cell surface proteins.
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Introduction
Colorectal cancer (CRC) is one of the most prevalent forms of cancer
with new cases and 500,000 deaths annually [1]. It remains the third
most common cancer in men and women in the United States [2]. In
30% to 40% of CRC patients, metastases are confined to the liver, and
for one quarter to one third of patients who are able to undergo resection
of liver metastases, the median survival after resection is between 24 and
40 months [3]. Thus, this high rate of liver metastases has transformed
treatment and evaluation and needs to be aggressively addressed to im-
prove cure rates.
Numerous studies have implicated aberrant function of the receptor
tyrosine kinaseMET in the progression andmetastasis of human tumors
including carcinoma of the pancreas, stomach, prostate, ovary, breast,
hepatocarcinoma, gastrinoma, melanoma, osteosarcoma, and CRC
[4]. The most frequent occurrence in human tumors is the increased
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expression of MET in the absence of autocrine HGF production [5].
Increased MET signaling in early stage CRC is a common occurrence,
whereas elevated MET expression/amplification in advanced disease is
linked to metastatic progression, which, consequently, makes it a viable
target for a significant subset of advanced CRC [6,7].MET, which is the
receptor of hepatocyte growth factor (HGF), is known to be responsible
for controlling the invasive growth program during embryogenesis and
in malignant cancer cells [4,5]. MET specifically stimulates cell scatter-
ing, invasion, protection from apoptosis and angiogenesis and therefore
has become a candidate for targeted therapeutic intervention [8]. Several
pharmaceutical companies have successfully discovered and developed
small molecule inhibitors of MET, which currently are being tested in
clinical trials [8]. Although one therapeutic antibody against HGF has
entered the clinic, the discovery of therapeutic antibodies against MET
has been very difficult, and antibodies that compete with HGF typically
act as agonists by dimerizing the receptor [9]. As a consequence, thera-
peutic antibodies (e.g., 5D5) were engineered to be monovalent to be
developed for clinical settings [10].
Whereas screening antibodies for HGF inhibition typically results
in antibodies with agonist activity, in the present study, we tested an
alternative approach. We hypothesized that, in cancer cell lines with a
very high level of MET expression, the receptor exists, at least par-
tially, in a ligand-independent active conformation. Therefore, we
used a cell-based panning strategy against cancer cell lines with a ge-
nomic amplification of the MET locus. We identified two antibodies
that synergistically inhibit MET signaling in vitro and in vivo and
display therapeutic efficacy in a variety of tumor models. Our ap-
proach could be expanded to drug discovery efforts against other cell
surface proteins.
Materials and Methods
General Materials
HuCAL GOLD library was from Morphosys (Martinsried, Ger-
many) [11]. Recombinant human HGF was purchased from Peprotech
(Rockyhill, NJ). Recombinant humanMET/Fc chimeric protein (extra-
cellular domain of MET, rMET-ECD-FC) was purchased from R&D
Systems (Minneapolis, MN), rMET-ECD-HIS was obtained by stably
overexpressing MET-ECD-H in 293-F (Invitrogen, Carlsbad, CA) cells
and purifying collected supernatants to homogeneity. Antibodies raised
against the following proteins were used: MET polyclonal rabbit anti-
body (prAb) C-12 (Santa Cruz Biotechnology, Santa Cruz, CA), phospho-
MET (monoclonal rabbit antibody (mrAb) 3D7), phospho-AKT (mrAb
193H12), phospho-MAPK (mrAb 197G2) were from Cell Signaling
(Danvers, MA), and SHC (prAb) and phosphotyrosine (monoclonal
mouse antibody (mmAb 4G10)) were from UBI (Billerica, MA). Phos-
phospecific and total protein ELISA kits for MET-(Y1230/Y1234/
Y1235), MET-(Y1349), AKT1-(S473), and ERK1/2 were purchased
from Invitrogen. As a control antibody, we used a murine IgG1 antibody
(1B711) that recognizes a hapten, trinitrophenol. The cell lines A549,
SNU-5, and H441 were obtained from ATCC (Manassas, VA), human
umbilical vein endothelial cells (HUVECs) were from Cambrex (Charles
City, IA) and cultured according to the suppliers’ protocols. Collagen I–
coated culture dishes and Matrigel were from BD Biosciences (Bedford,
MA). DELFIA-EuTDA cytotoxicity reagents were from Perkin-Elmer
(Waltham, MA). TaqMan assays for HGF, MET, GUS-B, High-Capacity
cDNA Archive Kit and TaqMan PCR master mix were from Applied
Biosystems (Foster City, CA).
HGF/MET Blocking Assay
Maxi-sorp 384-well microtiter plates (Nunc, Rochester, NY) were
coated with recombinant human HGF (1 μg/ml × 25 μl; R&D Sys-
tems) at room temperature for 2 hours at 30°C. After washing the
wells once with PBS–0.2% Tween-20 they were blocked with 5%
PBS/milk for 1 hour. Anti-MET antibodies (FAb) were preincubated
with MET-FC (25 ng per well) at room temperature for 1 hour. The
FAb/MET-FC mixtures was then added to the HGF-coated wells
and allowed to incubate for 1 hour at room temperature on a rocker
and washed three times with PBS–0.2% Tween-20. The secondary
antibody (goat antihuman FC, HRP-conjugated) was added at
1:5000 dilution and allowed to incubate for 1 hour at room temper-
ature. Washing was done as above. Fifty microliters of substrate was
added per well until a yellow color developed. The reaction was
stopped with 50 μl of 1 M H2SO4, and the absorbance at 450 nm
was determined with a standard plate reader.
Antibody-Dependent Cellular Cytotoxicity Assay
Blood was collected from normal volunteers and mixed with 33%
(v/v) volume of PBS. The mixture was layered onto a Ficoll gradient
and centrifuged at 400g for 40 minutes. Peripheral blood mononu-
clear cells were collected at the interface and washed thrice in PBS.
GTL-16 cells were europium-labeled according to the manufacturer’s
protocol and plated at a density of 10,000 cells per well in 50 μl in a
96-well U-bottomed plate and were incubated with the indicated anti-
MET antibodies (50 μl) at 37°C for 30 minutes. Peripheral blood
mononuclear cells were added to triplicate wells in a volume of
100 μl at an effector/tumor cell ratio of 100:1 and were incubated at
37°C for 4 hours. Target maximum fluorescence was determined by
lysing the cells with 10 μl of lysis buffer, whereas target spontaneous
fluorescence was determined in the absence of antibody and effector
cells. The percentage of specific cell lysis mediated by the antibodies
was calculated as the percentage of cell lysis in the antibody-treated
group: (experimental EM615nm− target spontaneous) / (targetmaximum −
target spontaneous) × 100.
Western Immunoblot Analysis (HUVEC) and ELISAs (A549)
Western blot analysis was done as described previously [12]. Briefly,
HUVEC or A549 cells were plated onto culture plates and serum-
starved for 24 hours. Cells either were left untreated or were pretreated
with the indicated IgGs (30 μg/ml) for 1 hour after stimulation with
20 ng/ml recombinant human HGF for 15 minutes at 37°C. After
HGF stimulation, the cells were lysed; lysates were cleared before protein
concentrations were determined.
Phosphospecific and total protein ELISAs were carried out according
to the manufacturers’ protocol. Phosphospecific values were normalized
by total protein content of the gene of interest.
FACS Experiment with R13 and R28
GTL-16 cells were nonenzymatically detached from cell cul-
ture plates, washed, and blocked with PBS/2% fetal calf serum for
30 minutes before incubating with the antibodies. One hundred
micrograms of R13 and of R28 were chemically conjugated with
fluorochrome AF-647 following the supplier’s protocol (Invitrogen).
Cells were then incubated with unlabeled and/or labeled R13/R28
at the indicated concentrations for 30 minutes at room temperature.
After extensive washing, cells were resuspendend in PBS/2% fetal calf
serum and analyzed by FACS.
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Proliferation and Migration Assays
Humanumbilical vein endothelial cells were plated at 8 × 104 cells/ml
(proliferation assay) or 2.5 × 105 cells per well (migration assay) onto
Collagen I–coated 96- or 24-well culture plates in complete media
(serum and growth factors; EGM-2), incubated for 24 hours, and sub-
sequently serum-starved for 24 hours in EBM-2 supplemented with
0.5% fetal bovine serum. For HGF-induced studies, HUVECs were
preincubated with R13/28 (30 μg/ml) or SU11274 (1 μM) for 1 hour
before adding HGF (50 ng/ml). Cells were incubated for 7 days, and
cell number was quantified using Cell-Titer-Glo Reagent (Promega,
Madison, WI) according to the manufacturer’s protocol. For migration
assays, a single scrape was made in the confluent monolayer in each
well as described previously [13].
Assaying Hypoxia
Staining for hypoxic regionswas performed as reported previously [14].
Briefly, to measure hypoxia, pimonidazole hydrochloride (HypoxyProbe;
NPI, Burlington, MA), which forms long-lived protein adducts at partial
pressure of oxygen less than approximately 10mmHg, was injected intra-
peritoneally at 60 mg/kg into NOD/SCID or nu−/− mice 1 hour before
sacrifice. Tumors were then processed for histologic analysis, and tumor
sections (5 μm thick) were stained using antipimonidazole antibody.
Photographs were taken using a BX51 microscope (Olympus, Center
Valley, PA).
Xenograft Transplantation and Experimental
Metastasis Experiments
OMP-C12, 27, and 28 are colon tumor xenograft lines used in
this study, and they were established at OncoMed Pharmaceuticals
by adhering to procedures described previously [15]. Immunocom-
promised male NOD/SCID mice were used for the establishment of
OMP-C12, 27 and 28 tumor xenografts and female nu−/− (Swiss CD-1)
mice were used for the GTL-16 tumor and experimental metastasis
model (Harlan, Indianapolis, IN). Mice were subcutaneously injected
on the right flank with 50,000 (for OMP-C12, 27, and 28) or 1 ×
107 viable cells (GTL-16), respectively. Once the tumor has reached a
size between 65 and 200 mm3, mice were randomized.
Experimental metastasis assays were performed as described previ-
ously [16] with the exception that GTL-16-luc were used, and tumor
burden in mice was visualized by noninvasive imaging with an
IVIS200 instrument (Caliper, Mountain View, CA), as previously
published [17]. Antibodies were administered weekly or as indicated,
and tumors were measured twice weekly. Tumor volume was calcu-
lated as described [15]. All the experiments were performed on
groups of at least 10 animals per experimental point. Animal experi-
ments were performed in accordance with protocols approved by the
OncoMed Pharmaceuticals Institutional Review Board – Animal
Care and Use Committee.
Global Gene Expression Analysis
Global gene expression profiling analysis was performed on Affy-
metrix HG-U133 plus 2.0 microarray (Affymetrix, Santa Clara, CA).
Three independent RNA samples of C27 xenograft whole tumors
from the control and treatment groups were isolated and hybridized
to the microarrays according to the manufacturer’s instructions.
Scanned array background adjustment and signal intensity normali-
zation were performed with Gene Chip–Robust Multiarray Averag-
ing algorithm in the open-source bioconductor software (www.
bioconductor.org). Genes differentially expressed (P < .05 and fold
change >2.0) between the two groups were identified with Bayesian
t-test [18].
Median Effect and Combination Index Analysis
Drug interactions were analyzed using CalcuSyn (Biosoft, Cam-
bridge, United Kingdom). This software calculates the median effect
dose, Dm (analogous to the IC50), of the drug combinations using the
median effect equation. Determination of synergy or antagonism was
based on the multiple drug effect equation of Chou and Talalay [19]
and was quantified by the combination index (CI).
Statistical Analysis
Data are expressed as the mean and mean ± SEM. Group means
were compared using Student’s two-tailed unpaired t test. Probability
(P) values of <.05 were interpreted as significantly different. Statistical
analyses were performedby usingMicrosoft Excel (Microsoft, Redmond,
WA) and GraphPad Prism (GraphPad Software, Inc., La Jolla, CA).
Results and Discussion
Our hypothesis was that, to obtain functional inhibitory antibodies
againstMET, the conformation ofMET has to be in its active and func-
tional conformation. Overexpression of receptor tyrosine kinases leads
to multimerization of a subfraction of receptors and their subsequent
activation [20]. The difficulty lies in enriching for FAbs, which recognize
the active MET conformation, block binding of HGF without activat-
ing the inactive receptors. Therefore, we set out to identify antagonistic
anti-MET antibodies by using the HuCAL phage display library and
performing cell-based panning strategies [21] (Figure 1). We chose
GTL-16 [22] and SNU-5 cancer cell lines owing to their high endoge-
nous expression level of functional MET and their sensitivity to MET
inhibition [23]. Moreover, by using two distinct cell lines, one adherent
(GTL-16) and one suspension cell line (SNU-5), enrichment of cell
surface receptors other than METwould be minimized. To increase
Figure 1. Panning strategy for inhibitory MET antibodies. Using the
Morphosys HuCAL GOLD FAb library, functional anti-MET antibodies
R13 and R28 were discovered using a series of novel selections
against human cancer cell lines (GTL-16, SNU-5), which possess a
MET amplicon (“active” MET), and recombinant Met extracellular
domain (rMET-ECD-FC/H). Initially, all selections were initiated on
GTL-16 cells (first round). The resultingoutputwas split and selections
continued with three different strategies: I) rMET-ECD-FC→ GTL-16;
II) rMET-ECD-H→ rMET-ECD-H; III) SNU-5→ rMet-ECD-FC. The hit
rate percentage (ELISA positive hits per 96-well plate) is indicated for
each output. Please note that R28 was the only FAb from strategy III.
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antibody specificity for the dimeric or monomeric form of the receptor,
we also used recombinant extracellular domain ofMETeither as human
Fc-fusion protein (rMET-ECD-FC) or as a 6× His-tagged protein
(rMET-ECD-H), respectively. We started by panning the first round
on live unfixed GTL-16 cells (Figure 1, I–IV ). To enrich for leads,
which would bind the dimeric or monomeric but presumably active
state of MET, we panned then either on rMET-ECD-FC and GTL-
16 (Figure 1, I ) or panned two subsequent rounds on rMET-ECD-H
(Figure 1, II ), respectively. In strategy III, the second panning roundwas
performed on SNU-5 and then further divided in two more rounds on
rMET-ECD-FC (Figure 1, III ). We discovered two specific anti-MET
FAbs R13 (KD[FAb] = 3.5 nM) and R28 (KD[FAb] = 48 nM). Inter-
estingly, R13 was obtained multiple times from strategies I and II,
whereas R28 was discovered exclusively in output III but not from I
or II. Epitope analysis revealed that only R13 binds to the SEMA do-
main of MET-ECD, whereas interestingly, R28 exclusively binds to the
full-length molecule (Figure W1). Because it is known that the SEMA
domain of MET-ECD is critical for HGF binding, our analysis suggests
that R13 is a direct HGF competitor [24]. However, R28 also competes
with HGF but does not bind to the critical SEMA domain of MET-
ECD, indicating that R28 recognizes an epitope in its tertiary confor-
mation. Therefore, binding of R28 to a tertiary structure of MET-ECD
could lead to a conformational stabilization of the receptor, which pre-
vents HGF binding to MET. Moreover, extensive efforts using selected
subdomains of the rMET-ECD or starting the panning with recombi-
nant protein instead of live cells always increased the hit rate but did not
yield any FAbs with inhibitory properties (data not shown). This sug-
gests that both the rMET-ECD and MET-ECD on cell lines exist in
its native conformation, but the difference lies in its state of activity:
“active” conformation onMET-dependent cells, whereas “inactive” con-
formation in its recombinant form.
We then performed a dose-response of R13 and R28 for their
ability to block HGF binding to MET in a protein-protein interaction
assay (Figure 2). Recombinant human HGF was passively immobilized
to 384-well plates and used to capture rMET-ECD-FC preincubated
with R13, R28, or a combination of both (Figure 2A). We observed
that R13 and R28 with an IC50 of 8.88 nM and 30.3 nM, respec-
tively, blocked ligand binding to MET (Figure 2A, green and blue lines).
Figure 2. Combination of R13 and R28 synergistically inhibit HGF-binding to MET and induce ADCC. The effect (y-axis) of anti-MET anti-
bodies R13 (green crosses), R28 (blue circles), and a combination of R13/28 (red ×’s) on blocking HGF binding to MET (A) and eliciting
antibody-dependent cellular cytotoxicity in GTL-16 cancer cells (C) is shown for increasing doses of each antibody or antibody combination
(x-axis; nM). The effect at each dose is marked with its corresponding symbol, and a dose-effect curve generated by curve fitting the data
points for each antibody. A conservative isobologram demonstrates that the antibody combination R13/28 acts synergistically to block HGF
binding to MET (B) and to induce ADCC (D). The ED50 (red ×), ED75 (green crosses), and ED90 (blue circles) are graphed. CI = 1 indicates an
additive effect; <1, synergy; >1, antagonism. Results are shown for the mutually exclusive assumption of modes of activity of R13 and
R28; however, applying the alternative assumption showed the same pattern of results. ED indicates effective dose.
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Interestingly, the combination of R13 and R28 in a ratio of 1:5 more
potently abrogated HGF binding to METwith an IC50 of 4.44 nM
(Figure 2A, red line). Isobologram analysis revealed that the effect is syn-
ergistic, as the combination effectively induced either a 75% or a 90%
effective dose (ED75 or ED90) response that is well below the ED90 values
induced by R13 or R28 alone (Figure 2B). Moreover, the CI value for
ED90 and ED75 is 0.39 and 0.52, respectively, strongly suggesting that
R13 and R28 act synergistically to inhibit ligand binding (Table W1).
It has been shown that therapeutic antibodies, such as anti–HER2
antibody (trastuzumab), not only abrogate signaling pathways but
also induce antibody-dependent cellular cytotoxicity (ADCC), which
significantly contribute to their antitumor activity in patients [25].
After reformatting R13 (KD[IgG] = 0.9 nM) and R28 (KD[IgG] =
1.9 nM) onto an IgG1 framework, we then tested them in ADCC
assays with GTL-16 as target cells (Figure 2, C and D). R13 and R28
induced an ADCC with IC50 values of 479 nM and 3.77 μM,
whereas the antibody combination strongly induced an ADCC with
an IC50 of 58.9 nM (Figure 2C ). Isobologram analysis and calcula-
tion of the CI values showed that the effect is strongly synergistic
because the CI values at ED75 and ED90 were 0.04 and 0.02, respec-
tively (Figure 2D and Table W1). These experiments demonstrate
the synergistic properties of R13 and R28 in inhibiting HGF-MET
binding and in inducing an ADCC response.
Because the HGF-MET axis plays a crucial role in angiogenesis
and human umbilical vein endothelial cells (HUVECs) display high
HGF response capability [26], we tested R13 and R28, both on an
IgG1 framework, in cell-based HGF-induced phosphorylation
wound healing and proliferation assays (Figure 3). To compare effi-
cacy of R13 and R28, we also included the small molecule inhibitor of
MET SU11274 as a positive control at 1 μM [27,28]. First, HUVECs
were serum-starved for 24 hours, preincubated with the antibody com-
bination R13/R28 or SU11274 for 1 hour at 37°C, and then stimu-
lated with 20 ng/ml HGF for 15 minutes. We then analyzed the
phosphorylation level of MET, of the downstream signaling molecules
SHC and AKT1, and of ERK1. We observed that the HGF-induced
tyrosine phosphorylation of MET, SHC, AKT1, and ERK1 was abro-
gated as efficiently by the antibody combination R13/28 as by
SU11274 at 1 μM (Figure 3A, upper panels, compare lane 2 to lanes 3
and 4 ). Hepatocyte growth factor–induced proliferation assays were
then performed to test the potential long-term inhibitory effect of
R13/28 on HUVECs. We observed that antibody combination R13/28
inhibited HGF-induced proliferation by 69% (Figure 3B). Additionally,
we performed wound healing assays with the MET-overexpressing
cell line H441 and observed that wound healing was inhibited by
50% (Figure W2). We then used the HGF-sensitive lung cancer cell
line A549 to test the inhibitory capability of the antibody combination
R13/28 [29]. The extent of phosphorylation at the tyrosine residues
Y1230/1234/1235 in the kinase domain and Y1349 in the cyto-
plasmic domain of MET and the phosphorylation of AKT1 at serine
residue S-473 and ERK1/2 at threonine residues T185 and Y187 were
quantified, and IC50 values were calculated (Table W1). The similarity
of IC50 values in blocking the phosphorylation of Y1230/1234/1235
of MET and of AKT1 (MET-Y1230/1234/1235, IC50 = 49.5 nM vs
AKT1-S-473, IC50 = 34.8 nM) indicates that inhibition of MET
kinase activity directly results in the inhibition of AKT1. A similar
correlation can be observed between IC50 values of the inhibition
of Y1349 phosphorylation and ERK1/2 activation at T185 and
Y187 (MET-Y1349, IC50 = 254 nM vs ERK1/2-T185/Y187, IC50 =
208 nM). This demonstrates that R13 and R28 abrogate MET sig-
naling, resulting in the attenuation of crucial downstream signaling
transducers thus leading to the inhibition ofMET-mediated physiologi-
cal responses.
Because the observed inhibitory effects are synergistic and the anti-
bodies do not compete for the same epitope (Figure W1), we hypothe-
sized that one antibody decreases the flexibility of MET, thereby
enabling the other antibody to block the HGF binding site. We rea-
soned that one antibody would increase the binding of the other anti-
body to cells expressing MET in its active form. Therefore, we tested
our hypothesis by titrating in one unlabeled antibody (R13 or R28) to
the other AF647-conjugated antibody (R28 or R13) and then measur-
ing the mean fluorescence intensity (MFI) on GTL-16 cells (Fig-
ure 3C ). We observed that the ΔMFI values of AF647-conjugated
R28 increased by increasing amounts of unlabeled R13. Because the
KD values remained unchanged (data not shown), this suggests that
R13 increases the antigen accessibility of R28 for MET on GTL-16
cells, which leads to an increase in ΔMFI values. Conversely, unlabeled
R28 did not increase R13-induced ΔMFI on GTL-16 cells. Now, we
have to note that without crystal structure of either antibodies R13
and R28 with the full-length molecule MET, the detailed mechanism
remains elusive, but structural studies are underway to clarify the pro-
posed mechanism. However, taken together, this experiment indicates
that antibody R13 facilitates the binding of R28 on GTL-16 cells,
thereby potentiating the binding of R28 to MET-ECD and “locking”
it into a nonfunctional receptor.
Consequently, we initiated proof-of-concept studies in vivo using
GTL-16 cells and our colorectal tumor bank collection, which was
established from patient primary tumors and passaged in NOD/
SCID mice. First, we checked the RNA expression level of MET
and HGF in our colon tumors (Figure W3). It has been reported that
an increased expression of MET in the absence of autocrine pro-
duced HGF correlates with a metastatic phenotype and poor prog-
nosis [5]. It has also been shown that MET protein expression is
significantly higher in most primary adenocarcinomas of the colon
than adjacent mucosa and that its expression level could serve as
an early-stage invasion and regional metastasis marker [30,31]. In
concordance with previous reports, we observed that colon tumors
do not express the HGF transcript, which indicates that in CRC
HGF is predominantly provided by the tumor-surrounding stroma
(Figure W3). We then chose to test R13/28 in GTL-16, C12,
C27, and C28 owing to their high MET expression levels and their
intrinsic growth rates in vivo. Firstly, mice were subcutaneously in-
jected with viable cells, and once the tumor reached a size between
65 and 200 mm3, mice were randomized and subsequently treated
with R13/28. We then tested the antibody combination R13/28 in a
therapeutic relevant setting and observed that R13/28 was effective in
inhibiting tumor growth in GTL-16, C12, C27, and C28 (Figure 4,
A–D). Testing R13 and R28 individually showed no inhibitory effect
on tumor growth (data not shown). Furthermore, histologic assess-
ment showed extensive hypoxic areas in R13/28-treatment groups
when compared with control C27 tumors (Figure 5A). Even more
pronounced effects were observed when we repeated the experiment
with GTL-16 cells: the combination R13/28 strongly inhibited
GTL-16 tumor growth and increased hypoxic regions almost over
the entire tumor surface area, especially in the center of the tumor
(Figure W4). Healthy cells were only detectable at the rim of the
GTL-16 tumors. Our data indicate that inhibition of MET signal-
ing abrogated proangiogenic signals, which results in diminished tu-
mor growth. This mechanism resembles the treatment of tumors with
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Figure 3. Combination of R13 and R28 inhibit HGF-mediated phosphorylation of MET, AKT, ERK1/2, and proliferation in HUVECs (A, B).
Serum-starved HUVECs were either stimulated with HGF (20 ng/ml) for 15 minutes or pretreated with R13/28 (30 μg/ml) and SU11274
(SU, 1 μM) for 1 hour before HGF stimulation. Cell lysates were subjected to immunoprecipitation (IP) using antibodies against MET
(α-MET; A, left panel) and SHC (α-SHC; A, middle panel). Phosphorylations of AKT1 and ERK1/2 were analyzed by Western blot analysis
of whole cell lysates (WCLs) with anti–phospho-AKT antibody (α-p(S473)AKT1) (A, right top panel) or with phosphospecific anti-ERK1/2
antibody (α-p(T202/Y204)ERK1/2), respectively (A, right middle panel). Tyrosine phosphorylation was analyzed by Western blot analysis
withmonoclonal antiphosphotyrosine antibody (α-p(Y100)). Protein levels were checked by reblot analysis with antibodies againstMET,
SHC, or β-actin (A, lower panel). Serum-starved HUVECs were used in proliferation assays on Collagen I plates, pretreated with R13/28
(30 μg/ml) or SU11274 (SU, 1 μM), respectively, in the presence (black bars) or absence (white bars) of HGF (50 ng/ml) (B). Proliferation
rate was increased 2.2-fold (Student’s t-test, P < .05) in the presence of HGF. R13/28 suppressed HGF-induced proliferation to basal
level (Student’s t-test, P < .01) (B, compare black to white bars). Proliferation was measured after 7 days and was done twice in qua-
druplicates. Please note that R13/28–treated HUVECs are statistically equivalent to untreated cells. R13 enhances R28 avidity to MET
receptor on GTL-16 cells (C). AF647-conjugated R28 (black bars) or R13 (white bars) was used as FACS reagent to detect MET receptor
on GTL-16 cells. AF647-labeled antibodies (AF647-R28 or AF647-R13) were used at fixed concentrations (360 nM, AF647-R28; 20 nM,
AF647-R13) and unlabeled R13 (0.5 nM, 20 nM) or R28 (90 nM, 360 nM) was titrated in. Note that 20 nM of R13 increased MFI values
(ΔMFI) for AF647-R28 by 2.6-fold, whereas adding R28 to AF647-R13 did not show any effect. ΔMFI values were determined by sub-
tracting background MFI. NS indicates not stimulated. Arrows indicate the detected proteins. Bars, SD.
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anti-HER2 antibody trastuzumab, which leads not only to a decrease in
proangiogenic factors but also to a dramatic increase in thrombospondin,
a negative regulator of angiogenesis [32].
To gain more insight in the mode of action, we analyzed the gene
expression profile of R13/28–treated C27 tumors by microarray (Fig-
ure 5B). Interestingly, we observed that inhibition of HGF/MET path-
way significantly upregulated the known tumor suppressors KLF6,
CEACAM1, and BMP2 (2.3-, 2.1-, and 2.8-fold, P < .001) and
the negative regulator of phosphatidyl-inositol-3-OH-kinase (PI3K)
PIK3IP1 (2.3-fold, P < .001). Concurrently, SCF and SERPINE2, both
enhancers of proliferation and invasiveness, were significantly sup-
pressed (SCF, 2.4-fold; SERPINE2, 4.2-fold; P < .001). It has previously
been shown that the tumor suppressor functions of KLF6, CEACAM1,
and BMP2 are inactivated in CRC [33–36].Moreover, SCF/KITrecep-
tor signaling has been implicated in proliferation and invasiveness of
CRC through the PI3K/AKT pathway [37]. A recent report by Zhu
et al. [38] suggests that PIK3IP1 is a novel p110 interacting protein,
which directly down-modulates PI3K activity. Conversely, SERPINE2
has been involved in enhancing invasive potential of pancreas cancer
cells in nude mice [39]. One mode of action of R13/R28 could be
the restoration of the tumor suppressor function of KLF6, CEACAM1,
and BMP2, which would ultimately inhibit tumor progression. In
addition, R13/R28–induced PIK3IP1 could amplify the inhibition
of AKT1 phosphorylation and potentiate R13/R28–induced down-
regulation of SCF through abrogated PI3K activity, resulting in di-
minished antiapoptotic/migratory signaling.
It has previously been reported that inhibition of MET in GTL-16
strongly decreased lung metastases in vivo [16]. Therefore, we tested
the ability of R13 and R28 to increase survival by diminishing lung
metastases in an experimental metastasis model with GTL-16 cells
(Figure 6). Mice were injected with GTL-16 cells stably expressing
the luciferase (luc) gene [40] and treated weekly with R13/28 or con-
trol antibody 1B711. Treatment was stopped after 3 weeks, and the
disease recurrence was measured by noninvasive imaging every week.
After 70 days, five of seven mice were alive, and four of five showed
strong luc activity in the lungs, whereas all R13/28–treated animals
were alive and did not show any luc activity (Figure 6A). At day 170,
only one mouse in the R13/28 treatment group died, whereas in the
Figure 4. Combination of R13 and R28 significantly inhibits tumor growth of established human tumor xenografts in vivo. Established
GTL-16 (A), C12 (B), C27 (C), and C28 (D) tumors (subcutaneously, n = 10 per group) were treated at 45 mg/kg once a week with the
indicated antibodies (1B711 control antibody, black squares; R13/28, inverted triangles). R13/28 induced tumor growth inhibition (TGI) of
49% in GTL-16, 57% in C12, 56% in C27, and 41% in C28 tumors. Note that the used molar ratio of R13/R28 is 1:8, based on KD values
to rMET-ECD. Tumor volume (x-axis) is plotted over time (y-axis). Asterisks indicate significant tumor growth inhibition at day shown.
Student’s t-test, *P < .05, **P < .01, ***P < .001. Symbols indicate mean; bars, SEM.
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control group, six of seven mice died (Figure 6B). This suggests that
the antibody treatment with R13/28 either inhibited the extrava-
sation of the tumor cells and/or diminished the survival capabilities of
GTL-16 in the lungs, by preventing the binding of stromal-derived
HGF to MET, although murine HGF has a weaker activity in activat-
ing human METreceptor than the human counterpart. Another expla-
nation could be that R13 or R28 acts as an inverse agonist, thereby
shifting the equilibrium from the activated state toward the inactive
form of MET. This shift could then lead to a decrease in proliferation
and increase in the apoptotic rate of GTL-16 cells.
The discovery of fully human inhibitory antibodies against MET
has so far been difficult, probably because of the structural constraints
and limited accessibility to HGF binding sites. To best of our knowl-
edge, only a “one-armed” humanized antibody has entered clinical trials
[10].We have shown that the difficult therapeutic antibody targetMET
can be inhibited if alternative approaches using cell-based panning are
carried out. Because HGF has been shown to be an important proangio-
genic factor, antiangiogenic effects in addition to antitumor/metastatic
properties could therefore be expected for R13 and R28. In primary
colon tumors, anti-MET antibody combination R13/28 not only sig-
Figure 6. Combination of R13 and R28 inhibits lung colonization of GTL-16-luc cells and increases survival in nude (nu/nu) mice. After
intravenous injection of (1.25 × 106 cells per mouse) GTL-16-luc cells, bioluminescence images were acquired after luciferin administra-
tion (150 mg/kg, intraperitoneally) (A). Tumor recurrence and survival was observed for 170 days after cell injection. Antibodies were admin-
istered once weekly from day−1 to day 21, and animals were continuously imaged every 2 weeks. To reduce stress on the animals, control
antibodies 1B711 or R13/28 were injected 24 hours before mice were challenged with GTL-16 cells. Log-rank (Mantel-Cox) comparison
of survival plots indicated 80% survival of R13/R28 group versus 0% of 1B711 group at day 170 (P < .001). Please note that at day 70, all
mice in R13/28 group still remained tumor-free when compared with 1B711 group (B). Bar, treatment period of 21 days.
Figure 5. Combination of R13 and R28 significantly upregulates hypoxia in C27 colon tumors (A). Overviews of DAPI staining and detection
for hypoxic areas of representative tumor sections from 1B711- (top panel) and R13/28– (bottom panel) treated mice. Viable tumor cells are
equally present in 1B711- and in R13/28–treated tumors, indicated by the relatively uniform and dense DAPI stain (top left vs bottom left
panel). In R13/28–treated tumors, hypoxic regions (α-pimonidazole) are significantly more pronounced than in 1B711 treated tumors, which
contributes to tumor growth inhibition (bottom middle vs top middle panel). AF594-conjugated goat antirabbit F(Ab′)2 was used to detect
antipimonidazole antibody. Right panel is a composition of the two stains. Scale bars, 2.5 mm. Relative expression levels of selected genes
significantly regulated by R13/28 treatment in the C27 xenograft tumor model (B). The expression level of each gene was normalized by
z-score transformation across the samples in the control (CTRL) and treatment (R13/28) groups. Red and green indicate high and low
expression levels, respectively. The P value (PVal) of each gene is the probability of significant regulation of the gene by R13/28 by chance
using Bayesian t-test. Several interesting genes were highlighted by bold font and described in the text.
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nificantly inhibited tumor growth by upregulating hypoxia and tumor
suppressor genes but also ultimately increased survival by diminishing
the number of lung metastases, presumably by interfering with the
extravasation process or transition frommicrometastases tomacrometas-
tases through the inhibition of survival capabilities. Recent progress in
bispecific antibody design has been achieved, and we are now exploring
the possibility to fuse the inhibitory properties of R13 and R28 into one
therapeuticmolecule [41]. In conclusion, we have shown that, in various
colon cancer models, R13/28 show effective antitumor activity, which
warrants further investigation and may ultimately lead to a new thera-
peutic molecule for colon cancer and other deadly malignancies.
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Supplementary Data
Materials and Methods
IgG affinity measurements. FAb and/or IgG affinities were deter-
mined using a Biacore 2000 instrument (Biacore, Piscataway,NJ). Briefly,
Met ECD was immobilized on a CM5 chip using standard amine-based
chemistry (NHS/EDC). For each FAb and IgG, different concentrations
(100-1 nM) were injected over the Met ECD surface, and kinetic data
were collected over time. Data were fit using the simultaneous global fit
equation to yield affinity constants (KD) for each FAb and IgG.
Quantitative PCR. Briefly, total RNAwas prepared fromOncomed’s
in-house tumor collection according to Qiagen’s RNA isolation pro-
tocol (Valencia, CA). Total RNA was quantified, and was cDNA
prepared from total RNA samples using random primers from the
High-Capacity cDNA Archive Kit. Gene-specific primers and probes
against human GUS-B (VIC-label) served as an endogenous control.
Samples have been run in the 7900HT Fast Real-time PCR System
and analyzed in quadruplicates using RQ Manager software (Applied
Biosystems, Foster City, CA).
Figure W1. Epitope mapping of R13 and R28. The 384-well micro-
titer plates were coated with human recombinant proteins (MET-
ECD, SEMA, PSI-IPT) as described previously in Materials and
Methods section. Binding of R13 or R28 to individual domains
of MET was determined with a standard plate reader. Please note
that R28 exclusively binds to MET ECD, whereas R13 binds to the
SEMA domain of MET ECD. Neither bind to PSI-IPT. Black bars,
MET ECD; gray bars, SEMA; white bars, PSI-IPT.
Table W1. Summary of Inhibitory Effects of Anti-MET Antibodies.
Effect R13 (r) R28 (r) R13/28 (r)
HGF competition IC50 (nM) 8.88 (0.97) 30.3 (0.99) 4.44 (0.96)
HGF competition, CI values (ED75) N/A N/A 0.52
HGF competition, CI values (ED90) N/A N/A 0.39
ADCC, IC50 (μM) 0.48 (0.92) 3.77 (0.99) 0.06 (0.87)
ADCC, CI values (ED75) N/A N/A 0.04
ADCC, CI values (ED90) N/A N/A 0.02
MET IC50 (nM), Y1230/Y1234/Y1235 N/A N/A 49.5 (0.94)
MET IC50 (nM), Y1349 N/A N/A 254 (0.99)
AKT1 IC50 (nM), S473 N/A N/A 34.8 (0.94)
ERK1/2 IC50 (nM), T185/Y187 N/A N/A 208 (0.94)
Note that the linear correlation coefficient r of the median effect plots was added next to the
antibodies. Values of r > 0.85 were considered to indicate that measurement of the assay was
accurate and conformed to mass action law.
N/A indicates not available.
Figure W2. R13 and R28 inhibit HGF-mediated wound healing in H441 cells. H441 cells were seeded at a density of 3 × 105 cells per
well in a 24-well plate. Serum-starved H441 cells pretreated with R13/28 (30 μg/ml) or SU11274 (1 μM), respectively, were used in scrape
assays in the presence or absence of HGF (50 ng/ml). The scrape was monitored and photographed after 16 hours. Note that R13/28
treatment prevents HGF-induced wound closure similarly to SU11274, corroborating results in HUVECs (data not shown). The experi-
ment was performed twice, and a representative micrograph is shown. NS indicates not stimulated.
Figure W3. Expression analysis of MET and HGF in colon tumors. The analysis was performed using qualitative PCR (TaqMan) and
primers and probes specific for human MET and HGF. As templates, cDNA from tumor specimen was used and analyzed in quadru-
plicates. Expression analysis was normalized against human GUS-B. For this analysis, the level of relative expression for MET and HGF is
in comparison to the expression observed in the colon tumor specimen, OMP-C40. Please note that with the exception of C18 and C29
HGF-RNA-transcripts could not be detected, suggesting that HGF is not produced by the tumor. Asterisks indicate colon tumor models
treated with R13/28. Black bars, MET; white bars, HGF; bars, SD.
Figure W4. R13/28 significantly upregulates hypoxia in GTL-16 tumors. Overviews of hematoxylin staining and detection for hypoxic
areas of representative tumor sections from 1B711 (left panel) and R13/28 (right panel) treated mice. 1B711 treatment group shows
relatively uniform and dense hematoxylin stain (left vs right panel). However, in R13/28–treated tumors, healthy hematoxylin-stained
regions are almost absent and only detectable at the rim of the tumor mass. In contrast, R13/28–treated tumors display large hypoxic
regions (α-pimonidazole), especially in the center region of the tumor. Representative photographs are shown at 10- and 20-fold mag-
nifications. Scale bars: top panel, 500 μm; bottom panel, 200 μm.
